JPRN-jRCTs032230278招募中3 期
A sham-controlled, double-blind and parallel-group study of the efficacy and safety of AT-04 for endometriosis Phase III
Koga Kaori0 个研究点目标入组 50 人开始时间: 2023年8月4日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- Female
入选标准
- •(1) Patients 18 years of age or older at the time consent is obtained
- •(2) Premenopausal female patients
- •(3) Patients with endometriosis (patients must meet one of the following conditions. In addition, if the disease recurs after surgery, the patient must be diagnosed again with one of the following)
- •(1) Patients diagnosed with endometriosis by laparotomy or laparoscopy performed within 5 years prior to the start of treatment.
- •(2) Patients with endometriosis detected by MRI or ultrasonography (transvaginal, transabdominal, or transrectal) performed within 1 year prior to the start of treatment, including ovarian chocolate cysts.
- •(3) Patients with a diagnosis of clinical endometriosis based on either Douglas fossa induration, limited uterine mobility, or pelvic tenderness by internal or rectal examination performed prior to the start of treatment.
- •(4) Patients with dysmenorrhea or pelvic pain that is thought to be derived from endometriosis, at least one of which is judged by the principal investigator to be moderate or higher on the B&B rating scale prior to the start of treatment
- •(5) Patients with an average NRS (Numeric Rating Scale) score of 4 or higher for pain due to endometriosis during the 28 days prior to obtaining consent
- •(6) Patients who have not started any new treatment for endometriosis or changed the treatment (including prescription details, dosage and administration) during the 28 days prior to obtaining consent.
- •(7) Patients who, in the judgment of the Principal Investigator(s), have no evidence of acute deterioration of endometriosis during the 28 days prior to obtaining consent.
- •(8) Patients who have given written consent to participate in the research of their own free will.
排除标准
- •(1) Patients who used the following drugs within 8 weeks prior to obtaining consent
- •Clinical trial drugs or investigational drugs
- •GnRH analogs, danazol and aromatase inhibitors, selective estrogen receptor modulators
- •(2) Patients who have previously used alternating magnetic field therapy devices, including study devices
- •(3) Patients taking NSAIDs on a regular basis
- •(4) Patients with ovarian chocolate cysts greater than 10 cm and age greater than 40 years
- •(5) Patients with a history of bilateral oophorectomy
- •(6) Patients with significant irregular uterine bleeding or unexplained irregular uterine bleeding as determined by the principal investigator.
- •(7) Patients with uterine fibroids that, in the opinion of the Principal Investigator, require new treatment during the study period
- •(8) Patients with irritable bowel syndrome and/or lower abdominal pain due to severe interstitial cystitis
- •(9) Patients with a history or complications of severe hepatic disorder, jaundice, renal disorder, cardiovascular disease, endocrine system disease, metabolic disease, pulmonary disease, gastrointestinal disease, neurological disease, urological disease, immune disorder, psychiatric disease (especially depression-like symptoms), and suicide attempts due to such disorders
- •(10) Patients using life-supporting medical electrical equipment such as artificial heart lungs and pacemakers.
- •(11) Patients using medical electrical equipment such as electrocardiographs
- •(12) Patients participating in clinical trials or clinical studies of other drugs or medical devices
- •(13) Patients who need to be hospitalized for treatment
研究者
相似试验
已完成
3 期
A sham-controlled, double-blind, parallel-group, randomized trial of repetitive transcranial magnetic stimulation (rTMS) for major depressive disorder, followed by a semi-crossover open trial of rTMS.Major depressive disorder (Monopolar depression)JPRN-UMIN000007794Kinkou Hospital, Kanagawa Psychiatric Center90
进行中（未招募）
1 期
A double blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of acetylsalicylic acid combined with pseudoephedrine, compared with acetylsalicylic acid alone, and pseudoephedrine alone, on symptoms of pain and nasal congestion in patients with symptomatic upper respiratory tract infection.asal congestion and pain associated with viral upper respiratory tract infectionMedDRA version: 9.1 Level: LLT Classification code 10046308 Term: Upper respiratory tract infection viral NOSEUCTR2009-011355-46-GBBayer Consumer Care AG
尚未招募
不适用
Clinical investigation on effects of FSFW0121 on appetite and weight management in overweight/obese subjects.CTRI/2021/12/038615Akay Natural Ingredients Pvt Ltd
进行中（未招募）
不适用
A double blind, placebo controlled, parallel group study with an open label reference arm to assess the effects of intravenously administered AIN457 on ozone induced neutrophilia compared to placebo and oral corticosteroid in healthy volunteersHealthy volunteersEUCTR2008-002854-39-DEovartis Pharma Services AG24
进行中（未招募）
不适用
A double blind, placebo controlled, parallel group, multicenter study to assess the duration of action, safety and toleration of differing doses and combinations of immediate and modified release formulations of UK-369,003 and Cialis compared to placebo in adult male subjects with erectile dysfunction. - N/AMale Erectile DysfunctionEUCTR2004-001955-12-DEPfizer Pharma GmbH335